Addex Therapeutics and National Institute on Drug Abuse (NIDA) Enter Collaboration to Advance ADX71441 & ADX88178 in Drug Abuse and Addiction
Published: Nov 04, 2013
Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today entering a collaboration with the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH) to evaluate the pharmacology of ADX71441, a GABAB receptor positive allosteric modulator (PAM), and ADX88178, an mGlu4 PAM in preclinical models of drug abuse and addiction. The collaboration will evaluate Addex drug candidates, ADX71441 and ADX88178 in a battery of preclinical models to study their potential as treatments for nicotine and cocaine addiction.
Help employers find you! Check out all the jobs and post your resume.